CA-SYNACK
5.8.2019 18:02:10 CEST | Business Wire | Press release
New York Times reporter Jessica Bennett observed that the 2020 female Democratic candidates have largely avoided the phrase “glass ceiling” , prompting linguist Robin Lakoff to speculate that the phrase just “seems tired”. On the debate floor, action-oriented and empowering words like “persist” are replacing phrases like “glass ceiling” and the “stuck-ness” implicitly suggested by them. It’s not just in politics that women are intentionally working toward changing society’s perception of them in the workplace; it’s happening in cybersecurity too.
Today, women make up only 20% of the cybersecurity industry’s workforce. This largely untapped demographic could be the saving grace for an industry desperate for skilled labor and on pace to hit 3.5 million unfilled jobs by 2021 according to Cybersecurity Ventures. This is why today Synack launches their “Courageous Women CISO Initiative” which aims to encourage more women to enter the cybersecurity field; offer support by creating a strong network for women; and provide a platform for women to share their voice in the boardroom, across the aisles in policy, and from the podium at leading industry conferences. Synack will build upon efforts that aim to close the talent gap in other ways (like encouraging young women to enter into STEM fields) by empowering women to get to the forefront of cybersecurity innovation and lead the charge in making our organizations more secure. The company is also encouraging more women to apply to their elite Synack Red Team , the world’s best and most trusted crowd of ethical hackers.
“When the concept of harnessing a crowd of ethical hackers was novel, Synack found that women CISOs were 2x more likely to adopt crowdsourced security, which showed that female security leaders are willing to be bold and courageous when facing decisions that can make their organizations more secure. Cybersecurity is a field that needs more diversity in thought and action, and women are an underrepresented group. We need more female leaders in the field who have successfully navigated the industry to be examples and mentors to newcomers,” said Aisling MacRunnels, Synack CMO and Courageous Women CISO Initiative Chair.
Synack’s initiative aims to connect and empower security’s female change-makers through a series of networking events and opportunities to speak from the podium at industry-renowned conferences. Synack has partnered with Microsoft/M12, CyberWire and now Booz Allen Hamilton to host popular women’s networking events at Black Hat USA, RSA Conference, and Billington Cybersecurity Summit; later this week, the company will host their 3rd annual Women’s Brunch at Black Hat USA. Through these efforts, Synack aims to …
- Close the talent gap in cybersecurity by increasing the number of women entering the industry by 50% by 2022.
- Increase the number of women speaking at industry conferences, so that the percentage of female speakers is on par with the percentage of male speakers by 2022.
After the women’s lunch at the RSA Conference 2019, partners M12 and CyberWire said, “We had a great time with the Synack team today - if only every lunch could be filled with so many impressive women! A big thank you to our amazing hosts: Lisa Nelson, Microsoft Ventures and Aisling MacRunnels, Synack,” (M12), and “It is our pleasure to support and empower women in the field of cybersecurity!” (Cyberwire).
Synack’s Courageous Women CISO initiative was developed to bring female security leaders and executives together to support each other in having a bigger impact in their companies and industry. Through this initiative, Synack’s goal is to create an environment that fosters authentic conversations and provides a support network for women in cybersecurity. Let’s change the status quo in cybersecurity together - RSVP for upcoming events for women and learn more about Synack’s Courageous Women CISO Initiative here: https://go.synack.com/courageous-women-ciso.html .
About Synack
Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190805005459/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom